恩替卡韦对慢性乙型肝炎成人患者的评价

StephenW

       Expert Review of Gastroenterology & Hepatology
   

An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults
Original Articles
An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults

DOI:
    10.1586/17474124.2016.1125781

Hye Won Leeab, Jun Yong Parkabc & Sang Hoon Ahnabcd*
Publishing models and article dates explained

    Received: 20 Sep 2015
    Accepted: 25 Nov 2015
    Accepted author version posted online: 26 Nov 2015
    Published online: 08 Jan 2016


ABSTRACT

Entecavir is a nucleoside analogue of 2ʹ-deoxyguanosine whose intracellular triphosphate form inhibits replication of the hepatitis B virus. Entecavir is recommended as a first-line monotherapy option for nucleos(t)ide-naïve patients with HBeAg-positive or -negative chronic hepatitis B infection. Entecavir has a three-step mechanism of action: It maintains viral suppression with a greater than 90% chance of undetectable hepatitis B virus DNA during continuous therapy, improves liver histology, and reduces the risk of liver failure or hepatocellular carcinoma development. The safety profile of long-term entecavir therapy is favorable; however, its optimal treatment duration is unknown. Entecavir monotherapy is not a rescue option for patients with lamivudine/adefovir resistance or baseline lamivudine-resistant mutants; rather, combination treatment is recommended for patients with lamivudine/adefovir resistance.

胃肠病学和肝病学专家审查
恩替卡韦对慢性乙型肝炎成人患者的评价
原创文章
恩替卡韦对慢性乙型肝炎成人患者的评价
DOI：10.1586 / 17474124.2016.1125781
惠元Leeab，君永Parkabc及相勋安ABCD *
出版模式和文章日期解释收稿日期：2015年9月20号接受：2015年11月25号接受笔者版本在网上发布：2015年11月26日在线发布时间：2016年1月8日
抽象
恩替卡韦是2'-脱氧鸟苷，其细胞内三磷酸形式抑制乙型肝炎病毒复制的核苷类似物。恩替卡韦被推荐为核苷（酸）IDE初治患者HBeAg阳性或阴性慢性乙型肝炎病毒感染的一线单一疗法的选择。恩替卡韦有动作的三步机制：它保持病毒抑制与检测不到的乙肝病毒DNA中的大于90％的机会在连续治疗，改善肝组织学，并降低肝衰竭或肝癌发展的风险。的长期恩替卡韦疗法的安全性方面是有利的;然而，它的最佳治疗时间是未知的。恩替卡韦单药治疗是不适合的患者拉米夫定/阿德福韦酯耐药或基线拉米夫定耐药突变救援选项;相反，被推荐用于治疗拉米夫定/阿德福韦酯耐药联合治疗。